• OPEN AN ACCOUNT
Indian Indices
Nifty
25,541.80 24.75
(0.10%)
Sensex
83,697.29 90.83
( 0.11%)
Bank Nifty
57,459.45 146.70
( 0.26%)
Nifty IT
38,833.15 -116.85
( -0.30%)
Global Indices
Nasdaq
44,512.09 396.31
(0.90%)
Dow Jones
6,218.43 -7.52
(-0.12%)
Hang Seng
39,928.49 -558.90
(-1.38%)
Nikkei 225
8,785.33 24.37
(0.28%)
Forex
USD-INR
85.41 -0.32
(-0.37%)
EUR-INR
100.07 -0.25
(-0.25%)
GBP-INR
117.16 -0.49
(-0.42%)
JPY-INR
0.59 0.00
(-0.52%)

EQUITY - MARKET SCREENER

JMG Corporation Ltd
Industry :  Miscellaneous
BSE Code
ISIN Demat
Book Value()
523712
INE745F01011
3.1088636
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
N.A
154.5
14.31
EPS(TTM)
Face Value()
Div & Yield %
0.04
2.5
0
 

Carbogen Amic AG to co-invest in its manufacturing sites in Switzerland
Jun 06,2025
Dishman Carbogen Amcis' wholly owned subsidiary, CARBOGEN AMCIS AG, a pharmaceutical process development and Active Pharmaceutical Ingredient (API) and drug products manufacturing company, announced a strategic co-investment of more than CHF 25 million with a long-standing Japanese customer to expand manufacturing capabilities at its sites in Aarau and Neuland, Switzerland.

The investment will support the production of a drug linker for a commercial antibody-drug conjugate (ADC), enabling CARBOGEN AMCIS to meet rising global demand. As part of the agreement, both facilities will see significant equipment and infrastructure enhancements, including:

• Aarau site: installation of 850-litre reactors and 0.4 m² agitated filter dryers with supporting equipment. Completion is expected by Q1 2027.

• Neuland site: installation of 850-litre reactors and 0.4 m² agitated filter dryers with auxiliary systems. Completion is anticipated by Q3 2027.

This project builds on a previous joint funding agreement between CARBOGEN AMCIS and the same customer in April 2021 to develop a site extension at the Bubendorf site in Switzerland, reinforcing the strength of the relationship and their shared commitment to long-term growth.